Pharmaceutical Partnership Deal Terminations by GBIResearch

VIEWS: 11 PAGES: 119

More Info
									                  Pharmaceutical Partnership Deal Terminations
 Reference Code: GBIHC159MR                                                                                Publication Date: September 2011

                                     GBI Research found that in the period of January 2010 to June 2011, large pharmaceutical
                                     companies terminated a number of licensing agreements and partnerships with small pharma and
                                     biotech companies, mostly due to changes in their business strategies. These major pharma
                                     companies also continued to restructure their internal R&D (Research & Development) in an effort
                                     to cut costs and thereby reduce the impact of expiring patents and thus the reprioritization of
                                     pipeline products may further lead to the termination of deals for products that do not look very
                                     promising, or whose development is expensive and time-consuming.
                                     Change in Company Strategy was Responsible for 60% of the Deal Terminations
60% of the top deals
terminated in the period of           Top Partnership Deal Terminations, Reasons for Deal Terminations, 2010-2011
January 2010 to June
2011 were due to change                                                       Disagreement between
in company strategy                                                            licensor and licensee
                                                                                        5%
                                                                  Delay in drug
                                                                  development
                                                                      10%




                                                      Negative results in
                                                       safety/efficacy
                                                            25%
                                                                                                               Change in strategy
                                                                                                                     60%




                                      Source: GBI Research, Company Websites



                                     GBI Research found that changes in strategy by the major pharma companies has been the
                                     leading cause of termination for top deals in the period of January 2010 to June 2011, accounting
                                     for 60% of the total deals terminated in that period. Other causes of deal terminations were
                                     negative results in safety or efficacy testing, delays in drug development, and disagreements
                                     between licensor and licensee, accounting for 25%, 10% and 5% of the total deals terminated.
                                     Mergers and acquisitions, and review of pipeline products by big pharma companies lead to
                                     changes in their strategies and sometimes to decisions to terminate licensing agreements.
                                     Additionally, delays in drug development caused by the rejection of Marketing Authorization
                                     Applications (MAAs) or New Drug Applications (NDAs) by regulatory authorities lead to increases in
                                     the development costs of drug candidates, as sponsors are asked to conduct additional studies to
                                     determine the safety and efficacy of the drug, and this may lead to the termination of licensing
                                     agreements for those drug candidates.




Pharmaceutical Partnership Deal Terminations                                                                   GBIHC159MR /Published SEP 2011
                                                                                                                                           Page 1
                                                                            © GBI Research. This is a licensed product and is not to be photocopied
                                     Majority of Terminated Deals were in CNS and Infectious Diseases Therapeutic Areas

                                      Top Partnership Deal Terminations, Therapeutic Areas, 2010-2011

                                                                                Musculoskeletal
                                                                       Respiratory   5%
                                                                          10%                            Central Nervous System
                                                                                                                  25%


                                                       Metabolic Disorders
                                                              10%



                                                              Dermatology
                                                                 10%


                                                                                                         Infectious Disease
                                                                           Oncology                              25%
                                                                             15%

                                      Source: GBI Research, Company Websites



                                     Among the therapeutic areas of the top terminated deals for the period of January 2010 to June
                                     2011, both Central Nervous System (CNS) and Infectious Disease dominated the list of therapeutic
                                     areas with the top terminated deals. Each of them represented 25% of the total terminated deals.
                                     Oncology was placed in third position, representing 15% of the total terminated deals, followed by
                                     Dermatology, Metabolic Disorders, Respiratory, and Musculoskeletal therapeutic areas
                                     representing 10%, 10%, 10%, and 5% of the total terminated deals respectively. In nearly all the
                                     therapeutic areas, change in a company’s strategy was the cause of termination for most deals.
                                     Majority of Terminated Deals had Deal Values in the Range of $400m to $600m
                                     GBI Research found that most of the terminated deals in the period of January 2010 to June 2011
                                     had deal values in the range of $400m to $600m, with 40% of the terminated deals having deal
                                     values in this range. Some 30% of the terminated deals had deal values in the range of $200m to
                                     $400m, 30% of the terminated deals had deal values in the range of $200m to $400m, 15% of the
                                     terminated deals had deal values in the range of $0m to $200m, 10% of the terminated deals had
                                     deal values in the range of more than $1,000m, and 5% of the terminated deals had deal values in
                                     the range of $800m to $1,000m. There was no terminated deal in the range of $600m to $800m
                                     between January 2010 and June 2011.




Pharmaceutical Partnership Deal Terminations                                                                   GBIHC159MR /Published SEP 2011
                                                                                                                                           Page 2
                                                                            © GBI Research. This is a licensed product and is not to be photocopied
                                     1 Table of Contents
                                     1 Table of Contents ........................................................................................................................ 3
                                       1.1    List of Tables..................................................................................................................... 6
                                       1.2    List of Figures ................................................................................................................... 9
                                     2 Top Partnership Deal Terminations – Introduction .................................................................... 10
                                       2.1    Licensing Agreement – An Authorization ........................................................................ 10
                                       2.2    Termination of Licensing Agreements ............................................................................. 10
                                       2.3    GBI Research Report Guidance ..................................................................................... 11
                                     3 Top Partnership Deal Terminations – Trends ............................................................................ 12
                                       3.1    Reasons for Deal Terminations....................................................................................... 12
                                       3.2    Therapeutic Areas – Terminated Deals .......................................................................... 13
                                       3.3    Deal Values – Terminated Deals .................................................................................... 14
                                     4 Top Partnership Deal Terminations - Deals ............................................................................... 16
                                       4.1    GlaxoSmithKline Terminates Licensing Agreement with Actelion for Almorexant ........... 16
                                          4.1.1       Companies Overview .............................................................................................. 16
                                          4.1.2       Product Overview .................................................................................................... 17
                                          4.1.3       Deal Overview ......................................................................................................... 19
                                          4.1.4       Reason for Termination ........................................................................................... 20
                                       4.2    GlaxoSmithKline Terminates Co-Development Agreement with Targacept for
                                              Development of Neuronal Nicotinic Receptor Therapeutics ............................................ 20
                                          4.2.1       Companies Overview .............................................................................................. 21
                                          4.2.2       Product Overview .................................................................................................... 21
                                          4.2.3       Deal Overview ......................................................................................................... 23
                                          4.2.4       Reason for Termination ........................................................................................... 23
                                       4.3    Shire Terminates Licensing Agreement with Renovo Group for Juvista ......................... 24
                                          4.3.1       Companies Overview .............................................................................................. 24
                                          4.3.2       Product Overview .................................................................................................... 26
                                          4.3.3       Deal Overview ......................................................................................................... 28
                                          4.3.4       Reason for Termination ........................................................................................... 28
                                       4.4    Anacor Pharmaceuticals Terminates Licensing Agreement with Merck for AN2690....... 29
                                          4.4.1       Companies Overview .............................................................................................. 29
                                          4.4.2       Product Overview .................................................................................................... 31
                                          4.4.3       Deal Overview ......................................................................................................... 34
                                          4.4.4       Reason for Termination ........................................................................................... 34
                                       4.5    Novartis Terminates Licensing Agreement with Human Genome Sciences for Albuferon
                                               ........................................................................................................................................ 35
                                          4.5.1       Companies Overview .............................................................................................. 35
                                          4.5.2       Product Overview .................................................................................................... 37
                                          4.5.3       Deal Overview ......................................................................................................... 38
                                          4.5.4       Reason for Termination ........................................................................................... 39
                                       4.6    InterMune Terminates Licensing Agreement with F. Hoffmann-La Roche for ITMN-191 39
                                          4.6.1       Companies Overview .............................................................................................. 40
                                          4.6.2       Product Overview .................................................................................................... 42
                                          4.6.3       Deal Overview ......................................................................................................... 43
                                          4.6.4       Reason for Termination ........................................................................................... 44
                                       4.7    GTx Terminates Worldwide Licensing Agreement with Merck for Ostarine .................... 45
                                          4.7.1       Companies Overview .............................................................................................. 45
                                          4.7.2       Product Overview .................................................................................................... 46
                                          4.7.3       Deal Overview ......................................................................................................... 48
                                          4.7.4       Reason for Termination ........................................................................................... 48
                                       4.8    Aveo Pharmaceuticals Terminates Licensing Agreement with Merck for AV-299 ........... 49
                                          4.8.1       Companies Overview .............................................................................................. 49
                                          4.8.2       Product Overview .................................................................................................... 50
                                          4.8.3       Deal Overview ......................................................................................................... 53


Pharmaceutical Partnership Deal Terminations                                                                                             GBIHC159MR /Published SEP 2011
                                                                                                                                                                                Page 3
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                           4.8.4       Reason for Termination ........................................................................................... 53
                                        4.9    Merck KGaA Terminates Worldwide Licensing Agreement with Lpath for Asonep ......... 54
                                           4.9.1       Companies Overview .............................................................................................. 54
                                           4.9.2       Product Overview .................................................................................................... 56
                                           4.9.3       Deal Overview ......................................................................................................... 57
                                           4.9.4       Reason for Termination ........................................................................................... 57
                                        4.10 Portola Pharmaceuticals Terminates Licensing Agreement with Merck for Betrixaban .. 58
                                           4.10.1 Companies Overview .............................................................................................. 58
                                           4.10.2 Product Overview .................................................................................................... 59
                                           4.10.3 Deal Overview ......................................................................................................... 61
                                           4.10.4 Reason for Termination ........................................................................................... 61
                                        4.11 Celldex Therapeutics Terminates Licensing Agreement with Pfizer for Rindopepimut ... 62
                                           4.11.1 Companies Overview .............................................................................................. 62
                                           4.11.2 Product Overview .................................................................................................... 63
                                           4.11.3 Deal Overview ......................................................................................................... 66
                                           4.11.4 Reason for Termination ........................................................................................... 66
                                        4.12 Depomed Terminates Licensing Agreement with Abbott Laboratories for DM-1796....... 67
                                           4.12.1 Companies Overview .............................................................................................. 67
                                           4.12.2 Product Overview .................................................................................................... 70
                                           4.12.3 Deal Overview ......................................................................................................... 73
                                           4.12.4 Reason for Termination ........................................................................................... 73
                                        4.13 Sanofi Terminates Licensing Agreement with Metabolex for MBX-2982 ........................ 74
                                           4.13.1 Companies Overview .............................................................................................. 74
                                           4.13.2 Product Overview .................................................................................................... 75
                                           4.13.3 Deal Overview ......................................................................................................... 76
                                           4.13.4 Reason for Termination ........................................................................................... 76
                                        4.14 BioLineRx Terminates Licensing Agreement with Cypress Bioscience for BL-1020 ....... 77
                                           4.14.1 Companies Overview .............................................................................................. 78
                                           4.14.2 Product Overview .................................................................................................... 79
                                           4.14.3 Deal Overview ......................................................................................................... 82
                                           4.14.4 Reason for Termination ........................................................................................... 83
                                        4.15 Cilag Terminates Licensing Agreement with Basilea Pharmaceutica for Ceftobiprole .... 83
                                           4.15.1 Companies Overview .............................................................................................. 84
                                           4.15.2 Product Overview .................................................................................................... 85
                                           4.15.3 Deal Overview ......................................................................................................... 86
                                           4.15.4 Reason for Termination ........................................................................................... 87
                                        4.16 Roche Terminates Licensing Agreement with Ipsen for Taspoglutide ............................ 87
                                           4.16.1 Companies Overview .............................................................................................. 88
                                           4.16.2 Product Overview .................................................................................................... 88
                                           4.16.3 Deal Overview ......................................................................................................... 95
                                           4.16.4 Reason for Termination ........................................................................................... 95
                                        4.17 Roche Terminates Licensing Agreement with Transgene for Papilloma Vaccine TG4001
                                                ........................................................................................................................................ 96
                                           4.17.1 Companies Overview .............................................................................................. 96
                                           4.17.2 Product Overview .................................................................................................... 97
                                           4.17.3 Deal Overview ......................................................................................................... 97
                                           4.17.4 Reason for Termination ........................................................................................... 98
                                        4.18 Rigel Pharmaceuticals Terminates Licensing Agreement with Pfizer for R343 ............... 98
                                           4.18.1 Companies Overview .............................................................................................. 99
                                           4.18.2 Product Overview .................................................................................................. 100
                                           4.18.3 Deal Overview ....................................................................................................... 100
                                           4.18.4 Reason for Termination ......................................................................................... 100
                                        4.19 Abbott Laboratories Terminates Licensing Agreement with SkyePharma for Flutiform 101
                                           4.19.1 Companies Overview ............................................................................................ 102
                                           4.19.2 Product Overview .................................................................................................. 103

Pharmaceutical Partnership Deal Terminations                                                                                             GBIHC159MR /Published SEP 2011
                                                                                                                                                                                Page 4
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                          4.19.3 Deal Overview ....................................................................................................... 108
                                          4.19.4 Reason for Termination ......................................................................................... 108
                                       4.20 Merck Terminates Strategic Alliance with Intercell for V710 ......................................... 109
                                          4.20.1 Companies Overview ............................................................................................ 109
                                          4.20.2 Product Overview .................................................................................................. 110
                                          4.20.3 Deal Overview ....................................................................................................... 114
                                          4.20.4 Reason for Termination ......................................................................................... 114
                                     5 Top Partnership Deal Terminations - Appendix ....................................................................... 115
                                       5.1    Market Definitions ......................................................................................................... 115
                                       5.2    Abbreviations ................................................................................................................ 115
                                       5.3    Research Methodology ................................................................................................. 117
                                          5.3.1    Coverage ............................................................................................................... 117
                                          5.3.2    Secondary Research ............................................................................................. 118
                                          5.3.3    Primary Research .................................................................................................. 118
                                          5.3.4    Section-wise Research Methodology .................................................................... 118
                                          5.3.5    Expert Panel Validation ......................................................................................... 119
                                       5.4    Contact Us .................................................................................................................... 119
                                       5.5    Disclaimer ..................................................................................................................... 119
                                       5.6    Sources ......................................................................................................................... 119




Pharmaceutical Partnership Deal Terminations                                                                                        GBIHC159MR /Published SEP 2011
                                                                                                                                                                         Page 5
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                     1.1       List of Tables
                                     Table 1:    Top Partnership Deal Terminations, Reasons for Deal Terminations, 2010-2011 ......... 12
                                     Table 2:    Top Partnership Deal Terminations, Therapeutic Areas, 2010-2011 ............................. 13
                                     Table 3:    Top Partnership Deal Terminations, Comparative Analysis of Reasons for Deal
                                                 Terminations for Various Therapeutic Areas, 2010-2011 ............................................... 14
                                     Table 4:    Top Partnership Deal Terminations, Comparative Analysis of Deal Values of the Top
                                                 Terminated Deals, 2010-2011 ........................................................................................ 15
                                     Table 5:    Top Partnership Deal Terminations, Clinical Trial Details, Almorexant in Primary
                                                 Insomnia, 2006-2007 ..................................................................................................... 18
                                     Table 6:    Top Partnership Deal Terminations, Clinical Trial Details, Almorexant in Elderly Subjects
                                                 With Chronic Primary Insomnia, 2007-2008 ................................................................... 18
                                     Table 7:    Top Partnership Deal Terminations, Clinical Trial Details, Almorexant in Adult Subjects
                                                 With Chronic Primary Insomnia, 2008-2009 ................................................................... 19
                                     Table 8:    Top Partnership Deal Terminations, GSK-Actelion Licensing Agreement, Deal Value
                                                 ($m), 2008 ...................................................................................................................... 19
                                     Table 9:    Top Partnership Deal Terminations, GSK-Targacept Licensing Agreement, Deal Value
                                                 ($m), 2007 ...................................................................................................................... 23
                                     Table 10:   Top Partnership Deal Terminations, Clinical Trial Details, Juvista in Scars Following
                                                 Varicose Vein Removal, 2006-2009 ............................................................................... 27
                                     Table 11:   Top Partnership Deal Terminations, Clinical Trial Details, Juvista in the Non-Surgical
                                                 Improvement of Existing Scars, 2009-2010 ................................................................... 27
                                     Table 12:   Top Partnership Deal Terminations, Shire-Renovo Licensing Agreement, Deal Value
                                                 ($m), 2007 ...................................................................................................................... 28
                                     Table 13:   Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy Study of
                                                 Subjects With Onychomycosis of the Great Toenail, 2005-2007 ................................... 31
                                     Table 14:   Top Partnership Deal Terminations, Clinical Trial Details, Absorption and Systemic
                                                 Study of AN2690 in Patients With Moderate to Severe Onychomycosis, 2006-2007..... 32
                                     Table 15:   Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy Evaluation
                                                 of Topically Applied AN2690 Solutions for Subjects With Onychomycosis, 2006-2007 . 32
                                     Table 16:   Top Partnership Deal Terminations, Clinical Trial Details, Efficacy and Safety Evaluation
                                                 of AN2690 Topical Solution to Treat Onychomycosis of the Toenail, 2010-2012 .......... 33
                                     Table 17:   Top Partnership Deal Terminations, Clinical Trial Details, Efficacy and Safety of AN2690
                                                 Topical Solution to Treat Onychomycosis of the Toenail, 2011–2012............................ 33
                                     Table 18:   Top Partnership Deal Terminations, Merck-Anacor Licensing Agreement, Deal Value
                                                 ($m), 2007 ...................................................................................................................... 34
                                     Table 19:   Top Partnership Deal Terminations, Novartis-HGS Licensing Agreement, Deal Value
                                                 ($m), 2006 ...................................................................................................................... 38
                                     Table 20:   Top Partnership Deal Terminations, Roche-InterMune Licensing Agreement, Deal Value
                                                 ($m), 2006 ...................................................................................................................... 44
                                     Table 21:   Top Partnership Deal Terminations, Clinical Trial Details, Study of GTx-024 on Muscle
                                                 Wasting Cancer, 2007-2008 .......................................................................................... 47
                                     Table 22:   Top Partnership Deal Terminations, Merck-GTx Licensing Agreement, Deal Value ($m),
                                                 2007 ............................................................................................................................... 48
                                     Table 23:   Top Partnership Deal Terminations, Clinical Trial Details, A Phase I Dose-Escalation
                                                 Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma, 2008-2012.......... 51
                                     Table 24:   Top Partnership Deal Terminations, Clinical Trial Details, A Pharmacodynamic Study of
                                                 AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have
                                                 Liver Metastases, 2009-2011 ......................................................................................... 52
                                     Table 25:   Top Partnership Deal Terminations, Clinical Trial Details, Study to Evaluate AV-299
                                                 (Formerly SCH 900105) in Combination With Gefitinib in Subjects With Non-Small Cell
                                                 Lung Cancer (NSCLC), 2009-2012 ................................................................................ 52
                                     Table 26:   Top Partnership Deal Terminations, Merck-Aveo Licensing Agreement, Deal Value ($m),
                                                 2007 ............................................................................................................................... 53
                                     Table 27:   Top Partnership Deal Terminations, Clinical Trial Details, Safety Study of Asonep to
                                                 Treat Advanced Solid Tumors, 2008-2010..................................................................... 56
                                     Table 28:   Top Partnership Deal Terminations, Merck KGaA-Lpath Licensing Agreement, Deal
                                                 Value ($m), 2008............................................................................................................ 57
                                     Table 29:   Top Partnership Deal Terminations, Clinical Trial Details, Phase II Study of the Safety,
                                                 Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to
                                                 Warfarin, 2008-2009 ...................................................................................................... 60




Pharmaceutical Partnership Deal Terminations                                                                                          GBIHC159MR /Published SEP 2011
                                                                                                                                                                             Page 6
                                                                                     © GBI Research. This is a licensed product and is not to be photocopied
                                     Table 30: Top Partnership Deal Terminations, Clinical Trial Details, A Study to Determine the
                                               Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban in Patients With
                                               Mild, Moderate, and Severe Renal Impairment, 2009-2010 ........................................... 60
                                     Table 31: Top Partnership Deal Terminations, Clinical Trial Details, Evaluate the Pharmacokinetics
                                               and Safety of Betrixaban in Participants With Nonvalvular Atrial Fibrillation, 2010–2011
                                               ....................................................................................................................................... 61
                                     Table 32: Top Partnership Deal Terminations, Merck-Portola Licensing Agreement, Deal Value
                                               ($m), 2009 ...................................................................................................................... 61
                                     Table 33: Top Partnership Deal Terminations, Clinical Trial Details, Phase II Study of CDX-110 in
                                               Patients With Glioblastoma Multiforme, 2007-2011 ....................................................... 65
                                     Table 34: Top Partnership Deal Terminations, Clinical Trial Details, Chemotherapy, Radiation
                                               Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma
                                               Multiforme That Has Been Removed by Surgery, 2007-2013 ........................................ 65
                                     Table 35: Top Partnership Deal Terminations, Clinical Trial Details, Phase I Rindopepimut After
                                               Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas, 2011-2012 .... 66
                                     Table 36: Top Partnership Deal Terminations, Pfizer-Celldex Licensing Agreement, Deal Value
                                               ($m), 2008 ...................................................................................................................... 66
                                     Table 37: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy of
                                               Gabapentin in Diabetic Peripheral Neuropathy, 2006 .................................................... 70
                                     Table 38: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy of
                                               Gabapentin in Postherpetic Neuralgia, 2006-2007 ........................................................ 71
                                     Table 39: Top Partnership Deal Terminations, Clinical Trial Details, Study of Gabapentin Extended
                                               Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in
                                               Postmenopausal Women, 2007-2008 ............................................................................ 71
                                     Table 40: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Efficacy of
                                               Gabapentin in Postherpetic Neuralgia, 2008-2009 ........................................................ 72
                                     Table 41: Top Partnership Deal Terminations, Clinical Trial Details, Study of Gabapentin Extended
                                               Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in
                                               Postmenopausal Women, 2008-2009 ............................................................................ 72
                                     Table 42: Top Partnership Deal Terminations, Abbott-Depomed Licensing Agreement, Deal Value
                                               ($m), 2009 ...................................................................................................................... 73
                                     Table 43: Top Partnership Deal Terminations, Clinical Trial Details, Study to Evaluate the Efficacy,
                                               Safety, Tolerability, and Pharmacokinetics of MBX-2982 in Patients With Type 2
                                               Diabetes, 2009-2010 ...................................................................................................... 76
                                     Table 44: Top Partnership Deal Terminations, Clinical Trial Details, A Positron Emission
                                               Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor
                                               Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in
                                               Healthy Male Subjects Using [11C] Raclopride as PET Tracer, 2007 ............................ 80
                                     Table 45: Top Partnership Deal Terminations, Clinical Trial Details, Safety and Tolerability of BL-
                                               1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder,
                                               2007 ............................................................................................................................... 80
                                     Table 46: Top Partnership Deal Terminations, Clinical Trial Details, A Six-week, Randomized,
                                               Double-blind, Placebo-controlled, Parallel Group, Multi-centre, Phase II Study, 2008-
                                               2009 ............................................................................................................................... 81
                                     Table 47: Top Partnership Deal Terminations, Clinical Trial Details, Phase IIb-III Study of BL-1020
                                               Small Molecule for Schizophrenia, 2011 ........................................................................ 81
                                     Table 48: Top Partnership Deal Terminations, Clinical Trial Details, Safety, Tolerability and
                                               Efficacy Study of BL-1020 in Patients with Schizophrenia, 2011 ................................... 82
                                     Table 49: Top Partnership Deal Terminations, BioLineRx-Cypress Licensing Agreement, Deal
                                               Value ($m), 2010............................................................................................................ 82
                                     Table 50: Top Partnership Deal Terminations, Clinical Trial Details, Ceftobiprole in the Treatment
                                               of Resistant Staphylococcus Aureus Skin and Skin Structure Infections, 2005 ............. 85
                                     Table 51: Top Partnership Deal Terminations, Clinical Trial Details, Ceftobiprole in the Treatment
                                               of Resistant Staphylococcus Aureus Skin and Skin Structure Infections, 2005-2006 .... 86
                                     Table 52: Top Partnership Deal Terminations, Clinical Trial Details, A Study of Taspoglutide
                                               Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus
                                               Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both,
                                               2008-2011 ...................................................................................................................... 89
                                     Table 53: Top Partnership Deal Terminations, Clinical Trial Details, A Study of Taspoglutide
                                               Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus
                                               Inadequately Controlled With Diet and Exercise, 2008-2010 ......................................... 90



Pharmaceutical Partnership Deal Terminations                                                                                            GBIHC159MR /Published SEP 2011
                                                                                                                                                                               Page 7
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                     Table 54: Top Partnership Deal Terminations, Clinical Trial Details, A Study of Taspoglutide
                                                Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus
                                                Inadequately Controlled With Metformin Plus Pioglitazone, 2008-2010 ......................... 90
                                     Table 55: Top Partnership Deal Terminations, Clinical Trial Details, A Study of Taspoglutide
                                                Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus
                                                Inadequately Controlled With Metformin, 2008-2011 ..................................................... 91
                                     Table 56: Top Partnership Deal Terminations, Clinical Trial Details, A Study of the Safety,
                                                Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in
                                                Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus
                                                Sulphonylurea, 2008-2011 ............................................................................................. 91
                                     Table 57: Top Partnership Deal Terminations, Clinical Trial Details, A Study of the Effect of
                                                Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes, 2008................... 92
                                     Table 58: Top Partnership Deal Terminations, Clinical Trial Details, A Study of Taspoglutide in
                                                Type 2 Diabetic Patients, 2
								
To top